APA (7th ed.) Citation

Berger, R., Tolcher, A., Dorff, T., Okubo, S., Abraham, L., Reilly, R., . . . Powderly, J. (2024). 1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology, 35, S1000. https://doi.org/10.1016/j.annonc.2024.08.1741

Chicago Style (17th ed.) Citation

Berger, R., et al. "1660TiP First-in-human Study of ABBV-969, a Dual Variable Antibody-drug Conjugate (ADC), in Patients (pts) with Metastatic Castration-resistant Prostate Cancer (mCRPC)." Annals of Oncology 35 (2024): S1000. https://doi.org/10.1016/j.annonc.2024.08.1741.

MLA (9th ed.) Citation

Berger, R., et al. "1660TiP First-in-human Study of ABBV-969, a Dual Variable Antibody-drug Conjugate (ADC), in Patients (pts) with Metastatic Castration-resistant Prostate Cancer (mCRPC)." Annals of Oncology, vol. 35, 2024, p. S1000, https://doi.org/10.1016/j.annonc.2024.08.1741.